Lineage Cell Therapeutics, Inc. (LCTX)
Data as of , from SEC Form 4 filings.
See up to 3 months of LCTX. The 7-day demo opens the 1M and 3M ranges and puts LCTX on your watchlist.
Start 7-day demoData as of , from SEC Form 4 filings.
See up to 3 months of LCTX. The 7-day demo opens the 1M and 3M ranges and puts LCTX on your watchlist.
Start 7-day demo
Neal C. Bradsher - DirectorLineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
No Form 4 activity for LCTX in the last 90 days.
24 Form 4 filings on record, the earliest from Nov 22, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Neal C. Bradsher - Director | Grant or award | OPTION TO PURCHASE COMMON SHARES | 125,000 | $0.00 footnote F2 | - | |
| ||||||
| Anula Jayasuriya | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Michael H. Mulroy | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
 Deborah J. Andrews | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Angus C. Russell | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Dipti Amin | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Brian M. Culley - Officer | Open-market purchase | Common Shares | 15,000 | $1.63 footnote F1 | $24K | |
| ||||||
| Brian M. Culley - Officer | Grant or award | Employee Stock Option (Right to Buy) | 3,250,000 | $0.00 | - | |
| Jill Ann Howe - Officer | Grant or award | Employee Stock Option (Right to Buy) | 1,050,000 | $0.00 | - | |
| George A. Samuel III - Officer | Grant or award | Employee Stock Option (Right to Buy) | 900,000 | $0.00 | - | |
| Brian M. Culley - Officer | Option exercise | Common Shares | 31,250 footnote F1 | - footnote F1 | - | |
| Brian M. Culley - Officer | Tax withholding / forfeiture | Common Shares | 12,869 footnote F3 | $1.80 | $23K | |
| Brian M. Culley - Officer | Option exercise | Restricted Stock Units | 31,250 | $0.00 | - | |
| ||||||
| George A. Samuel III - Officer | Option exercise | Common Shares | 6,075 footnote F1 | - footnote F1 | - | |
| George A. Samuel III - Officer | Tax withholding / forfeiture | Common Shares | 2,502 footnote F3 | $1.80 | $5K | |
| George A. Samuel III - Officer | Option exercise | Restricted Stock Units | 6,075 | $0.00 | - | |
| ||||||
| Brian M. Culley - Officer | Grant or award | Common Shares | 8,925 footnote F1 | - footnote F1 | - | |
| Brian M. Culley - Officer | Tax withholding / forfeiture | Common Shares | 334 footnote F3 | $1.68 | $561 | |
| ||||||
| George A. Samuel III - Officer | Grant or award | Common Shares | 1,735 footnote F1 | - footnote F1 | - | |
| George A. Samuel III - Officer | Tax withholding / forfeiture | Common Shares | 65 footnote F3 | $1.68 | $109 | |
| ||||||
| Dipti Amin | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Anula Jayasuriya | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Angus C. Russell | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Michael H. Mulroy | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Deborah J. Andrews | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Neal C. Bradsher - Director | Grant or award | OPTION TO PURCHASE COMMON SHARES | 75,000 | $0.00 | - | |
| Jill Ann Howe - Officer | Open-market purchase | Common Shares | 15,000 | $0.59 | $9K | |
| George A. Samuel III - Officer | Open-market purchase | Common Shares | 15,000 | $0.60 | $9K | |
| Michael H. Mulroy | Open-market purchase | Common Shares | 40,000 | $0.57 | $23K | |
| Brian M. Culley - Officer | Open-market purchase | Common Shares | 40,000 | $0.60 | $24K | |
Lineage Cell Therapeutics, Inc. (LCTX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-02. The full record for LCTX runs to 24 Form 4 filings, the earliest from 2024-11-22. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
No insider purchases of LCTX were filed in the last 90 days. 5 purchases are on record for this company.
No insider sales of LCTX were filed in the last 90 days.
This page collects LCTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
